Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Daniel Faga sold 3,000 shares of Spark Therapeutics stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.02, for a total value of $255,060.00. Following the sale, the insider now owns 3,000 shares in the company, valued at $255,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Daniel Faga also recently made the following trade(s):

  • On Monday, July 24th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $70.00, for a total value of $210,000.00.
  • On Thursday, June 29th, Daniel Faga sold 4,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $62.71, for a total value of $282,195.00.

Spark Therapeutics, Inc. (NASDAQ:ONCE) opened at 81.71 on Thursday. Spark Therapeutics, Inc. has a 1-year low of $35.07 and a 1-year high of $85.26. The stock has a 50 day moving average price of $82.71 and a 200 day moving average price of $69.14. The stock’s market cap is $2.55 billion.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.75) by ($0.14). The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The firm’s revenue was up 14.7% compared to the same quarter last year. During the same period last year, the business posted ($1.04) EPS. On average, analysts predict that Spark Therapeutics, Inc. will post ($7.69) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Spark Therapeutics, Inc. (ONCE) Insider Sells $255,060.00 in Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/14/insider-selling-spark-therapeutics-inc-once-insider-sells-255060-00-in-stock.html.

Several research firms have commented on ONCE. Jefferies Group LLC began coverage on Spark Therapeutics in a report on Monday, July 10th. They issued a “buy” rating and a $85.00 target price on the stock. Cantor Fitzgerald set a $94.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, July 17th. ValuEngine downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 20th. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Zacks Investment Research raised Spark Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $83.77.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. boosted its position in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Spark Therapeutics during the 2nd quarter valued at $143,000. BNP Paribas Arbitrage SA boosted its position in Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 2,449 shares in the last quarter. Pacad Investment Ltd. boosted its position in Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new stake in Spark Therapeutics during the 1st quarter valued at $227,000. 91.01% of the stock is currently owned by institutional investors and hedge funds.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.